Freya Pharma Solutions Rebrands As Arletta Pharma Solutions, Signaling A New Era In Women’s Healthcare Innovation

Freya Pharma Solutions, a company dedicated to developing innovative therapies for women affected by Female Sexual Disorders (FSD), has announced that it will rebrand as Arletta Pharma Solutions, effective December 1, 2025. The new name marks a significant moment in the company’s evolution as it advances toward key clinical milestones and prepares for the final stages of securing regulatory approval for its therapies. CEO Nicole Hijnen explained that the rebranding reflects a natural transformation in the company’s growth. She noted that, much like a caterpillar becoming a butterfly, Arletta Pharma is entering a crucial new phase as it moves closer to fulfilling its mission of addressing a major unmet medical need that affects millions of women globally.

The choice of the name Arletta, inspired by a rare butterfly species, holds symbolic meaning within the context of women’s healthcare. Across cultures and medical disciplines, the butterfly often represents transformation, freedom, and beauty—values that align closely with women’s health journeys. From puberty and reproductive years to the transitions of perimenopause and postmenopause, women experience profound physiological shifts throughout their lives. These transitions highlight the importance of specialized medical approaches that understand and respect the complexity of female sexual health.

Arletta Pharma’s work to develop treatments for Female Sexual Interest/Arousal Disorder (FSIAD) reflects this understanding. The company is advancing multiple clinical programs, including its ongoing Phase II Clitoral Doppler Duplex Ultrasonography (CDU) study at Chaim Sheba Medical Center. Led by Prof. Cobi Reisman and Dr. Anna Padoa, the study is evaluating two testosterone–sildenafil dose combinations in premenopausal women with acquired, generalized FSIAD. 

By using clitoral Doppler duplex imaging to measure blood flow parameters, the study aims to generate preliminary data in the near term. In parallel, Arletta Pharma is preparing for its pivotal ALETTA study, to be conducted across 20 research sites in five European countries. Enrollment is expected to begin once financing arrangements are finalized—a major step toward achieving regulatory approval in Europe.

The company’s lead investigational therapy, Lybrido™, represents the culmination of fifteen years of research into female sexual dysfunction. Designed as an on-demand, dual-action treatment for FSIAD and Hypoactive Sexual Desire Disorder (HSDD), Lybrido™ incorporates a novel dual-route, dual-release formulation. The tablet combines a testosterone coating for sublingual absorption with an inner core of sildenafil, a PDE-5 inhibitor. Its delayed-immediate-release matrix ensures that the peak effects of sildenafil coincide precisely with the testosterone-induced increase in sexual motivation. This synchronized mechanism enhances genital arousal by boosting responsiveness to sexual stimuli, with therapeutic effects lasting between three and six hours.

Lybrido™ has already been studied extensively, including 20 Phase I and Phase IIa trials, as well as large-scale Phase IIb studies across 17 research sites in the United States. With its rebranding to Arletta Pharma Solutions and its continued scientific progress, the company is positioning itself to deliver the first truly innovative therapeutic option for women living with FSIAD. The transition to the Arletta identity signifies not just a new name, but the company’s readiness to enter its most promising and impactful chapter—one that brings it closer to delivering transformative therapies that address long-standing unmet needs in women’s sexual health.